The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.
T. Mok
Consultant or Advisory Role - AVEO
Honoraria - AVEO
Research Funding - AVEO
E. Tan
No relevant relationships to disclose
K. Park
No relevant relationships to disclose
J. Jac
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
M. Han
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
F. C. Payumo
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
M. Credi
Stock Ownership - AVEO
K. McKee
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
M. M. Cotreau
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
P. Bhargava
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
W. Slichenmyer
Employment or Leadership Position - AVEO
Stock Ownership - AVEO